Loop diuretics
A group of diuretics, medicines that act on the kidney. A US label says one of them inhibits the absorption of sodium and chloride in the kidney tubules, including the loop of Henle. The US label read for one loop diuretic lists swelling from fluid build-up in congestive heart failure, cirrhosis and kidney disease, and says the oral form may also be used for high blood pressure.
Also called Loop diuretic
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH descriptor D049994 (Sodium Potassium Chloride Symporter Inhibitors, last updated 2020-05-27) is recorded as a broad match: it is named for the mechanism, and its scope note describes agents that inhibit sodium-potassium-chloride symporters and act as diuretics. MeSH says excess use is associated with low blood potassium and high blood sugar. The label read is the US prescribing label of one brand-name furosemide tablet (application NDA016273, effective 2025-09-30 in openFDA); its openFDA record gives the established pharmacologic class Loop Diuretic. The label covers adults and pediatric patients for edema and adults for hypertension. This page gives no dose, no trial result and no guideline statement, and none of the label's warnings was recorded, including the warning on profound loss of water and electrolytes that opens its warnings section. Medicines of the group that have their own pages are filed under it.
Drugs in this class
3 drugs in this atlas are filed under Loop diuretics, with the registry trials and FDA regulatory decisions this atlas holds for each. With Loop diuretics itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- A US label says the medicine it describes inhibits the absorption of sodium and chloride in the kidney tubules, including the loop of Henle. MeSH says agents in this group act as diuretics.
Classification codes
-
D049994Sodium Potassium Chloride Symporter Inhibitors
Claims and evidence
Context Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic
- Recipient
- Mixed recipients
- Population
- Patients described in the indications section of the label: adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease, and adults with hypertension.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (US drug label)
- Life stage
- Adults and pediatric patients for edema; adults for hypertension, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults and pediatric patients with edema associated with congestive heart failure, cirrhosis of the liver or renal disease
- Adults with hypertension
- Excluded
- None stated
The US label of LASIX (furosemide tablets, Validus Pharmaceuticals LLC, application NDA016273; the version dated 2025-09-30 in openFDA) lists the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome, in adults and pediatric patients. It says oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. openFDA's record gives the established pharmacologic class Loop Diuretic. MeSH says agents of the matching descriptor act as diuretics.
Applies to Mixed recipients Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pharmacologic class name comes from openFDA's record of the label. Other loop diuretic labels list different uses. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- Edema and hypertension uses.
- Retrieved
- Source effective date
- 2025-09-30
- Source state
- Current
- Version fingerprint
ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].openfda.pharm_class_epc[0]
- How it applies
- Established pharmacologic class in openFDA: Loop Diuretic.
- Retrieved
- Source effective date
- 2025-09-30
- Source state
- Current
- Version fingerprint
ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250930.
- Retrieved
- Source effective date
- 2025-09-30
- Source state
- Current
- Version fingerprint
ed9855aad2ab51bda46903f2319af7d32d4fcf9954b059cd6afc33672d16a4f0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Supports MeSH scope note for descriptor D049994 (Sodium Potassium Chloride Symporter Inhibitors)
- Locator
- scopeNote.@value
- How it applies
- MeSH scope note: the agents act as diuretics.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
5b779b15d6a5e90ccf188a1787b22597dfb8060a2483888d21493018350e5ec7- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. Source: National Library of Medicine. This copy was fetched on 2026-11-09 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A US label lists fluid build-up from congestive heart failure as an indication: Heart failure
Applies to Mixed recipients Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic
The US label of LASIX (furosemide tablets, Validus Pharmaceuticals LLC, application NDA016273; the version dated 2025-09-30 in openFDA) lists the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome, in adults and pediatric patients. It says oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. openFDA's record gives the established pharmacologic class Loop Diuretic. MeSH says agents of the matching descriptor act as diuretics.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pharmacologic class name comes from openFDA's record of the label. Other loop diuretic labels list different uses. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact A US label says the oral form may be used for high blood pressure: Hypertension (high blood pressure)
Applies to Mixed recipients Adults and pediatric patients with edema, and adults with hypertension, as described in the US label of a loop diuretic
The US label of LASIX (furosemide tablets, Validus Pharmaceuticals LLC, application NDA016273; the version dated 2025-09-30 in openFDA) lists the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome, in adults and pediatric patients. It says oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. openFDA's record gives the established pharmacologic class Loop Diuretic. MeSH says agents of the matching descriptor act as diuretics.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The pharmacologic class name comes from openFDA's record of the label. Other loop diuretic labels list different uses. Contraindications, warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:loop-diuretics- Content hash
721311ab54f38eb0ea5ad1d622a83fb7f70046fdacf10f6b745fc7aae599c164